After Mizuho Securities and Cantor Fitzgerald gave Aerie Pharma (NASDAQ: AERI) a Buy rating last month, the company received another Buy, this time from Canaccord Genuity. Analyst Dewey Steadman maintained a Buy rating on Aerie Pharma today and set a price target of $86. The company’s shares opened today at $64.35.
According to TipRanks.com, Steadman is a 3-star analyst with an average return of 3.3% and a 38.3% success rate. Steadman covers the Healthcare sector, focusing on stocks such as ANI Pharmaceuticals Inc, Pacira Pharmaceuticals, and Perrigo Company plc.
Currently, the analyst consensus on Aerie Pharma is a Strong Buy with an average price target of $86.33, a 34.2% upside from current levels. In a report issued on August 9, Mizuho Securities also maintained a Buy rating on the stock with a $77 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $74.75 and a one-year low of $47.05. Currently, Aerie Pharma has an average volume of 404.4K.
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aerie Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of therapies for the treatment of patients with glaucoma and diseases of the eye. Its products include Rhopressa and Roclatan.
